Search Results - "Liebner, D."

TP53 mutational status is predictive of pazopanib response in advanced sarcomas by Koehler, K., Liebner, D., Chen, J.L.

“…To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with…”
Get full text

Immune related adverse events across cancer types: Incidence, risk factors and survival by Owen, D.H., Burkart, J., Patel, S., Wei, L., Tinoco, G., Liebner, D., He, K., Shields, P.G., Bertino, E.M., Presley, C.J., Johns, A., Folefac, E., Olencki, T., Carbone, D.P., Verschraegen, C., Otterson, G.A., Kendra, K.L.

Get full text

Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas by Raj, R., Kim, H., Xu, M., Roach, T., Liebner, D., Konieczkowski, D.J., Tinoco, G.

“…In this study, we describe the clinical presentation, patterns of care, and treatment outcomes for radiation-associated sarcomas (RAS) patients seen at our…”
Get full text

Scalp Irradiation with 3D-Milled Bolus: Dosimetric, Toxicity, and Oncologic Outcomes by Tocaj, G., Dibs, K., Jhawar, S.R., Baliga, S., Grecula, J.C., Mitchell, D.L., Palmer, J.D., Haglund, K.E., Andraos, T.Y., Zoller, W., Ewing, A., Bonomi, M., Bhateja, P., Tinoco, G., Liebner, D., Rocco, J.W., Old, M., Chakravarti, A., Konieczkowski, D.J., Blakaj, D.M., Gogineni, E.

“…Bolus is required when treating scalp lesions with photon radiation therapy. Traditional bolus materials face several issues, including air gaps and setup…”
Get full text

ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma by Van Tine, B.A., Butler, M.O., Araujo, D., Johnson, M.L., Clarke, J., Liebner, D., Odunsi, K., Olszanski, A.J., Basu, S., Brophy, F., Holdich, T., Trivedi, T., Amado, R.G., Hong, D.S.

Get full text

1670O - ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma by Van Tine, B.A., Butler, M.O., Araujo, D., Johnson, M.L., Clarke, J., Liebner, D., Odunsi, K., Olszanski, A.J., Basu, S., Brophy, F., Holdich, T., Trivedi, T., Amado, R.G., Hong, D.S.

“…This study (NCT03132922) evaluates safety, tolerability, and antitumor activity of ADP-A2M4, genetically engineered autologous specific peptide enhanced…”
Get full text

1670OADP-A2M4 (MAGE-A4) in patients with synovial sarcoma by Van Tine, B A, Butler, M O, Araujo, D, Johnson, M L, Clarke, J, Liebner, D, Odunsi, K, Olszanski, A J, Basu, S, Brophy, F, Holdich, T, Trivedi, T, Amado, R G, Hong, D S

“…Abstract Background This study (NCT03132922) evaluates safety, tolerability, and antitumor activity of ADP-A2M4, genetically engineered autologous specific…”
Get full text

1772PImmune related adverse events across cancer types: Incidence, risk factors and survival by Owen, D H, Burkart, J, Patel, S, Wei, L, Tinoco, G, Liebner, D, He, K, Shields, P G, Bertino, E M, Presley, C J, Johns, A, Folefac, E, Olencki, T, Carbone, D P, Verschraegen, C, Otterson, G A, Kendra, K L

Get full text

Phase I Study of Trametinib in Combination with Whole-Brain Radiation Therapy for Brain Metastases by Fabian, D., Wuthrick, E.J., Wei, L., Tan, J., Grecula, J.C., Welliver, M.X., Williams, T.M., Elder, J.B., Raval, R., Blakaj, D.M., Haglund, K.E., Bazan, J.G., Kendra, K.L., Liebner, D., Puduvalli, V., Giglio, P., Gonzalez, J., Arnett, A.L.H., Bell, E.H., Chakravarti, A., Palmer, J.D.

Get full text

Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A02 patients with synovial sarcoma and non-small cell lung cancer by Schoenfeld, AJ, Altan, M, Owonikoko, TK, D'Angelo, S, Ladle, BH, Noujaim, J, He, K, Liebner, D, Sacher, AG, Haanen, JBAG, Yachnin, J, Huang, C, Van Tine, BA, Hasan, A, Faitg, T, Butler, E, Shalabi, A, Attia, S, Araujo, DM

Get full text

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2) by Schoenfeld, Adam Jacob, Altan, Mehmet, Owonikoko, Taofeek K., D'Angelo, Sandra P., Ladle, Brian H., Noujaim, Jonathan Christopher, He, Kai, Liebner, David A., Sacher, Adrian G., Haanen, John B. A. G., Yachnin, Jeffrey, Huang, Chao H., Van Tine, Brian Andrew, Hasan, Aisha N., Faitg, Thomas H., Butler, Emily, Shalabi, Aiman, Attia, Steven, Araujo, Dejka M.

“…Abstract only TPS2661 Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy using a genetically modified T-cell receptor…”
Get full text

Multiple-Day Constancy As An Alternative To Pooling For Estimating Mark-Recapture Stopover Length In Nearctic-Neotropical Migrant Landbirds by Morris, SR, Liebner, DA, Larracuente, A M, Escamilla, E M, Sheets, H D

“…Capture-mark-recapture models require estimation of parameters that may be either constant or time-dependent. Open-population models have been adapted for use…”
Get full text

MULTIPLE-DAY CONSTANCY AS AN ALTERNATIVE TO POOLING FOR ESTIMATING MARK-RECAPTURE STOPOVER LENGTH IN NEARCTIC-NEOTROPICAL MIGRANT LANDBIRDS by Morris, Sara R, Liebner, David A, Larracuente, Amanda M, Escamilla, Erica M, Sheets, H. David

“…Capture-mark-recapture models require estimation of parameters that may be either constant or time-dependent. Open-population models have been adapted for use…”
Get full text

UTILITY OF OPEN POPULATION MODELS: LIMITATIONS POSED BY PARAMETER ESTIMABILITY IN THE STUDY OF MIGRATORY STOPOVER by MORRIS, SARA R., LARRACUENTE, AMANDA M., COVINO, KRISTEN M., MUSTILLO, MELISSA S., MATTERN, KATHRYN E., LIEBNER, DAVID A., SHEETS, H. DAVID

“…Open population models using capture-mark-recapture (CMR) data have a wide range of uses in ecological and evolutionary contexts, including modeling of…”
Get full text